ArticleACS biomaterials science & engineering2022
Injectable Hydrogel Containing Cowpea Mosaic Virus Nanoparticles Prevents Colon Cancer Growth.
Article in ACS biomaterials science & engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Nanoparticle-Hydrogel Composites for Precision Medicine.Cell biomaterials · 2026Article
- Gel-Based Drug Delivery Platforms: A Critical, Mechanistic Review of Design, Cross-Linking, and Disease-Specific Translation (2010-2026).Gels (Basel, Switzerland) · 2026Review
- Harnessing chitosan-based biomaterials for advanced cancer immunotherapy: from nanocarriers to tumor microenvironment modulation.Journal of nanobiotechnology · 2026Review
- Advanced hydrogel material for colorectal cancer treatment.Drug delivery · 2025Review
- Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations.European journal of medical research · 2025Review
- Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.Frontiers in bioengineering and biotechnology · 2025Review
- Hydrogel-Based Vaccines: A Promising Approach for Cancer Immunotherapy.International journal of nanomedicine · 2025Review
- Recent advances of injectable in situ-forming hydrogels for preventing postoperative tumor recurrence.Drug delivery · 2024Review
- Chitosan non-particulate vaccine delivery systems.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024Review
- Review
- Preparation of Cod Skin Collagen Peptides/Chitosan-Based Temperature-Sensitive Gel and Its Anti-Photoaging Effect in Skin.Drug design, development and therapy · 2023Article
- Cancer Immunotherapy and Delivery System: An Update.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Despite advances in laparoscopic surgery combined with neoadjuvant and adjuvant therapy, colon cancer management remains challenging in oncology. Recurrence of cancerous tissue locally or in distant organs (metastasis) is the major problem in colon cancer management. Vaccines and immunotherapies hold promise in preventing cancer recurrence through stimulation of the immune system. We and others have shown that nanoparticles from plant viruses, such as cowpea mosaic virus (CPMV) nanoparticles, are potent immune adjuvants for cancer vaccines and serve as immunostimulatory agents in the treatment or prevention of tumors. While being noninfectious toward mammals, CPMV activates the innate immune system through recognition by pattern recognition receptors (PRRs). While the particulate structure of CPMV is essential for prominent immune activation, the proteinaceous architecture makes CPMV subject to degradation
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.